Search - tctmd.com

Displaying 61 - 80 of 258

Sort: Relevancy | Date

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Niacin, When Broken Down by the Body, Can Spur Inflammation

Caitlin E. Cox

February 22, 2024

News Daily News

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Yael L. Maxwell

February 15, 2024

News Daily News

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

Todd Neale

February 14, 2024

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

L.A. McKeown

February 01, 2024

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Daily News

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

Yael L. Maxwell

December 13, 2023

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

Presentation TCT 2023

Lipoprotein(a): Why Measure and What to Do?

Presenter: Sotirios Tsimikas

October 26, 2023

Presentation TCT 2023

TCT 271: Characterizing pathophysiological patterns of coronary artery disease among Individuals with Elevated Lipoprotein(a).

Presenter: Mick Renkens

October 25, 2023

Presentation TCT 2023

TCT 1006: Significant multivessel disease in a very young patient presenting with ACS and extremely high lipoprotein (a): early recognition and how to revascularize?

Presenter: Lars Witte

October 25, 2023

Presentation TCT 2023

TCT 486: Achieving Low-Density Lipoprotein Cholesterol Goal and Very Long-Term Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Presenter: Hong Nyun Kim

October 24, 2023

News Daily News

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

Yael L. Maxwell

October 12, 2023

Advertisement

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Niacin, When Broken Down by the Body, Can Spur Inflammation

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

February 2024 Dispatch for the CV Team

Less Is More: Lp(a) Much More Atherogenic Than LDL

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

What’s Going to Be Hot at AHA 2023

Lipoprotein(a): Why Measure and What to Do?

TCT 271: Characterizing pathophysiological patterns of coronary artery disease among Individuals with Elevated Lipoprotein(a).

TCT 1006: Significant multivessel disease in a very young patient presenting with ACS and extremely high lipoprotein (a): early recognition and how to revascularize?

TCT 486: Achieving Low-Density Lipoprotein Cholesterol Goal and Very Long-Term Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content